Evotec’s cost-cutting drive has reached its pipeline. The company axed around 30% of its asset portfolio and offloaded ...

Q4 2024 Earnings Call Transcript April 17, 2025 Evotec SE misses on earnings expectations. Reported EPS is $-0.12 EPS, ...

Evotec shares climb after the company posted 2024 earnings in line with its expectations, and said that it seeks to refocus on drug discovery and pre-clinical development. Shares rose 7.2% at 6.24 ...

Evotec is a drug discovery partnership firm that has a contract development and manufacturing organization, or CDMO, business, in addition to an innovative drug development program focused on ...

Hamburg, Germany, 17 April 2025: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced its financial results for FY 2024, provided guidance for FY ...

In a report released today, Christian Ehmann from Warburg Research maintained a Buy rating on Evotec (0IRF – Research Report), with a price ...

Dr Christian Wojczewski, Chief Executive Officer of Evotec, said: "Evotec's ambitious new direction paves the way for sustainable profitable long-term growth. We are refocusing Evotec on its core ...

Ladies and gentlemen, welcome to the Evotec SE Full-Year Result 2024 Analyst Call. I am Yusuf, the Chorus Call operator. I would like to remind you that all participants will be in a listen-only ...

Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth Strategy builds on technology and science leadership, focusing on high-growth ...

Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth Strategy builds on technology and science leadership, focusing on high-growth, high-value ...